Appili Therapeutics Inc., the Halifax company dedicated to fighting infectious diseases, has raised $10.25 million by selling shares and warrants to mainly institutional investors.
The fundraising round – the company’s first since it listed on the TSX Venture exchange in June – comes after the company has undergone a series of changes in senior executives and its board. The company will use the money to advance the four drug candidates in its portfolio.
“Funds from this offering put Appili in a very solid position to keep delivering on the value-driving milestones in our pipeline,” said